A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

Official Title

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma


The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma.

Trial Description

Primary Outcome:

  • Objective response rate (ORR)
Secondary Outcome:
  • Progression free survival (PFS)
  • Duration of response (DOR)
  • Time to response (TTR)
  • Incidence, timing, severity of treatment-emergent adverse events (TEAEs)
This is an open-label, randomized active control study of BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed or refractory follicular lymphoma. Randomization is 2:1 and participants will be stratified by the number of prior lines of therapy (2
  • 3 vs > 3),rituximab-refractory status and geographic region (China vs ex-China). The study will evaluate the efficacy, as measured by overall response rate by independent review, safety and tolerability. Pharmacokinetic profile of BGB-3111 and obinutuzumab combination therapy will also be evaluated

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society